More than 900 people without cognitive alterations from the Alfa Study, which has the support of the "la Caixa" Foundation, have participated in the research.
The study, which used data from almost 400 participants of the ALFA+ Study, determines that the biomarkers p-tau231 and p-tau217 measured in the blood are suitable for indicating brain changes related to the amyloid protein in people without cognitive symptoms.
Our research center will have a notable presence at the Alzheimer's Association International Conference (AAIC 2022), which will be held between July 31 and August 4 in San Diego.
Research helps to better understand the relationship between biomarkers of Alzheimer’s disease and the pathophysiological mechanisms that are altered in their early stages.
BBRC researchers present four posters and three oral presentations at INS 2022, which this year took place in Barcelona under the theme “Global Innovations in Science and Practice”.
The research center of the Pasqual Maragall Foundation, the BBRC, participates in the project, together with seven other European centers.
During the congress, basic, clinical and translational aspects of research in neurodegenerative diseases were discussed.
The participants of the conference were able to see first-hand the center's new Fluid Biomarkers and Translational Neurology laboratory.
La investigadora tindrà la responsabilitat de desenvolupar, validar i implementar biomarcadors en sang per a la detecció precoç de l’Alzheimer.